Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you use combination of weekly low dose carboplatin and Taxol in patient with small cell lung cancer with poor performance status or cytopenia?
Related Questions
What factors would determine which currently approved agent to use as a first line treatment for a stage IV ROS-1 fusion patient with the approval of repotrectinib?
How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
Would you offer adjuvant treatment to a Stage IB NSCLC, margins negative but with findings of STAS (tumor spread through airway spaces)?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
Would you consider ALK-directed TKI for a ALK L1198F point mutation in a patient with metastatic lung adenocarcinoma after progressing through first line chemoimmunotherapy?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
How would you approach first-line treatment in metastatic NSCLC for a patient with ALK-EML4 V3a/b variant and MSI-high status?